Sudden death in children receiving Norpramin: a review of three reported cases and commentary.
The 1990 "package insert" for Norpramin, the Merrell Dow Pharmaceuticals Inc., brand of desipramine, was changed to include the following statement in the Adverse Reactions section, "There has been a report of an 'acute collapse' and 'sudden death' in an eight-year-old (18 kg) male, treated for two years for hyperactivity. There have been additional reports of sudden death in children." The purpose of this commentary is to review what is known about the three reported cases of sudden death and to discuss the implications of these tragedies for children receiving treatment with tricyclic drugs.
Riddle
M A
MA
Yale Child Study Center, New Haven, CT 06510-8009.
Nelson
J C
JC
Kleinman
C S
CS
Rasmusson
A
A
Leckman
J F
JF
King
R A
RA
Cohen
D J
DJ
D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000523:psychology; D002648:Child; D003645:Death, Sudden / Q000209:etiology*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D003891:Desipramine / Q000008:administration & dosage / Q000009:adverse effects*; D006323:Heart Arrest / Q000139:chemically induced; D006801:Humans; D008297:Male; D012307:Risk Factors; D014693:Ventricular Fibrillation / Q000139:chemically induced
D003891:Desipramine